research centers


Search results: Found 2

Listing 1 - 2 of 2
Sort by

Article
Clinical Outcomes improvement of refractory Obsessive compulsive disorder by use Olanazapine

Author: Hafidh Mohammed Farhan
Journal: Al-Qadisiyah Medical Journal مجلة القادسية الطبية ISSN: 18170153 Year: 2012 Volume: 8 Issue: 14 Pages: 221-229
Publisher: Al-Qadisiyah University جامعة القادسية

Loading...
Loading...
Abstract

More than half of the patients with obsessive- compulsive disorder (OCD) remain unimproved by Serotonin-Reuptake inhibitors(SSRI). objective of this study was to examine whether addition of atypical antipsychotic (olanzapine ) to Sertraline is useful for patients with OCD who do not respond to SSRI monotherapy.1.According to (DSM IV-TR criteria) , 20 patients are diagnosed as OCD and did not responded to Sertraline at dose 100-150mg/day 2.Olanazapine was additional treatment , start 2.5mg/day at first month then 5 mg/day for last two months of study .3.Treatment response was assessed using the Yale-Brown Obsessive-Compulsive Scale (YBOCS) at end of each months of study16 of 20 patients respond to the olanzapine augmented sertraline therapy . The mean baseline YBOCS score of 32.75 dropped to a mean of 21.75 at endpoint for male with reduction 12.81% from baseline.While in female, the mean baseline YBOCS score of 33.83 dropped to a mean of 21.67 at endpoint with reduction 17.06% from baseline.Treatment-refractory OCD Patients may benefit from addition of olanzapine to ongoing SSRI therapy.

أكثر من نصف المرضى الذين يعانون من الوسواس القهري لا تتحسن حالتهم الصحية بالاستخدام مثبطات أعادة الامتصاص مادة السيروتونين .أن الهدف من هذه الدراسة هو فحص مادة اولانزيبم كمادة إضافية إلى مادة الاسيرتالين في معالجة الوسواس القهري الذي لا يستجيب إلى مثبطات إعادة امتصاص السيروتونين وتمت الدراسة بطريقة: 1.عشرون مريض تم تشخيصهم بمرض الوسواس القهري وفق (DSM-IV-TR) حيث أنهم لم يستجيبوا إلى العلاج بمادة الاسيرتالين بجرعة 100-150 ملغم يوميا.2.تستخدم مادة اولانزيبم كمادة تضاف لعلاج السابق بجرعة 2.5 ملغم خلال العلاج ولمدة شهر ثم تزداد الجرعة إلى 5 ملغم لشهرين المتبقية من الدراسة.3.يتم تقيم الاستجابة لعلاج باستخدام معيار (Yale-Brown Obsessive-Compulsive Scale (YBOCS)) .كانت النتائج هي ستة عشر مريض من مجموع عشرون تم إخضاعهم لدراسة اظهروا استجابة لعلاج اولانزيبم كمادة تزيد من فعالية الاسيرتالين في معالجة الوسواس القهري حيث يظهر نزول معدل الخط الأساسي لمعيار (YBOCS) لدى الذكور من(32,75 ) إلي (21,75) أي بنسبة 12,81% . بينما يبدأ نزول معدل الخط الأساسي من (33,83) الي (21,67) لدى الإناث أي بنسبة 17,06%.استنتج ان هنالك فائدة من إضافة مادة اولانزيبم إلي مادة الاسيرتالين في معالجة الوسواس القهري المتعنت لعلاج.

Keywords

OCD --- Olanazapine --- Sertraline --- YBOCS


Article
Effects of Olanazapine and Haloperidol on Serum Malondialdehyde, Prolactin Level, Blood Glucose and Lipid Profile in Schizophrenic Patients
آثار أولانازابين وهالوبيريدول على مصل Malondialdehyde ، مستوى البرولاكتين ، نسبة الجلوكوز في الدم والدهون في مرضى الفصام

Authors: Sirwan Kamil Ali --- Muhammad A. Hassan --- Kawa F. Dizaye
Journal: Zanco Journal of Medical Sciences مجلة زانكو للعلوم الطبية ISSN: 19955588/19955596 Year: 2010 Volume: 14 Issue: 2 Pages: 13-21
Publisher: Hawler Medical Univeristy جامعة هولير الطبية

Loading...
Loading...
Abstract

Background and Objectives: The association of the atypical antipsychotics with hypergly-cemia, elevated lipids, and weight gain was recognized soon after the introduction of clozapine and has become of increased concern as the use and uses of atypical antipsy-chotics have been expanded. The aim of the present study was to investigate the preva-lence of diabetes, dyslipidaemia, lipid peroxidation and hyperprolactinemia in Olanzepine treated patients in comparison with patients treated with haloperidol.Methods: Fifty patients were selected randomly from psychiatric inpatient clinic in Erbil city in Iraqi Kurdistan Region between November 2007 and June 2008.All patients were diagnosed as schizophrenia, and none of them were in acute severe state. Thirty Schizophrenic patients received Haloperidol orally as typical antipsychotic and 20 patients received Olanazapine orally as atypical antipsychotic for a minimum of one month. Fasting blood samples for the assessment of serum malondialdehyde (MDA), lipid profile, fasting blood glucose (FBG) and prolactin levels were obtained after one month of the drug prescribing time. From those fifty patients, 16 patients were selected to follow them prospectively over a mean period of time of 112 days for olanzapine and 75 days for haloperidol. The prospective study includes FBG, lipid profile, BMI and serum MDA.Results: The prevalence of hyperprolactinaemia and lipid peroxidation was higher in Haloperidol treated patients. Whereas, the prevalence of diabetes and dyslipidaemia were higher in Olanazapine treated patients, The mean level of BMI of the Olanazapine group was significantly higher than BMI of the Haloperidol group. There was 6.66 % prevalence of DM in Olanazapine treated patients, but there was no prevalence of DM in Haloperidol treated patients. There was no incidence of diabetes mellitus in the prospective study for both Haloperidol and Olanazapine treated patients.Conclusions:No absolute evidence indicates that the atypical antipsychotic Olanazapine is the cause of diabetes, since the glucose levels of all patients were within normal range and there was no incidence of diabetes in the prospective study in spite of their higher weight and body mass index.

Listing 1 - 2 of 2
Sort by
Narrow your search

Resource type

article (2)


Language

English (2)


Year
From To Submit

2012 (1)

2010 (1)